-
Mashup Score: 4Ixabepilone Plus Bevacizumab Generates Survival Benefit and Responses in Platinum-Resistant/Refractory Ovarian Cancer - 24 day(s) ago
Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Dr DeBernardo on an Ovarian Cancer Patient Case Study - 2 month(s) ago
Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer. @ClevelandClinic #ovca https://t.co/Q8mDmFxd21
-
-
Mashup Score: 1Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer - 4 month(s) ago
Roisin E. O’Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Roisin E. O'Cearbhaill, MD, of @MSKCancerCenter, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer. #ovca https://t.co/vbt9wQ2YKz
-
-
Mashup Score: 1Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer - 4 month(s) ago
Roisin E. O’Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Roisin E. O'Cearbhaill, MD, of @MSKCancerCenter, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer. #ovca https://t.co/vbt9wQ2YKz
-
-
Mashup Score: 0
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the approval of a Type II variation application for rucaparib as a frontline maintenance in patients with advanced ovarian cancer who have responded to first-line, platinum-based chemotherapy, irrespective of BRCA mutational status.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EU Panel Recommends Rucaparib for Frontline Maintenance in Advanced Ovarian Cancer #ovca #oncology https://t.co/ecJmFbEnqQ
-
-
Mashup Score: 1
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the September 26, 2023, data cutoff, efficacy-evaluable patients with advanced ovarian cancer experienced a disease control rate of 91% and a median progression-free survival of 170 days with CYT-0851 and capecitabine. #oncology #medtwitter #ovca https://t.co/0krhlA0q9s https://t.co/WY5vhK8sYJ
-
-
Mashup Score: 0
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer. #oncology #medtwitter #ovca https://t.co/0krhlA0q9s
-
-
Mashup Score: 1
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CYT-0851 Plus Capecitabine Demonstrates Efficacy in Advanced Ovarian Cancer #oncology #medtwitter #ovca https://t.co/0krhlA0XZ0
-
-
Mashup Score: 0FDA Grants Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer - 7 month(s) ago
The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. #ovca #oncology https://t.co/c7gyCo28VD
-
-
Mashup Score: 0FDA Grants Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer - 7 month(s) ago
The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The safety and early efficacy of ABV-001 is under investigation in a phase 1/2 study of patients with metastatic or unresectable, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. #ovca #oncology https://t.co/c7gyCo28VD https://t.co/ivQCtWnjet
-
Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer. #ovca https://t.co/yTxrdJrzCE